ScholarLens Back to search
2011•Current Opinion in OncologyRequires access

New developments for treatment and prevention of bone metastases

Jean‐Jacques Body

Open publisher page 30 citations

Abstract

PURPOSE OF REVIEW: To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. RECENT FINDINGS: The bisphosphonate zoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. SUMMARY: Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.

About this research paper

What this paper is about

PURPOSE OF REVIEW: To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. RECENT FINDINGS: The bisphosphonate zoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. SUMMARY: Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.

Why it matters

OpenAlex reports 30 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

PURPOSE OF REVIEW: To provide a critical review of recent trials of bone resorption inhibitory drugs (bisphosphonates and denosumab) for the treatment and the prevention of bone metastases in solid tumors. RECENT FINDINGS: The bisphosphonate zoledronic acid is now part of the standard treatment for metastatic bone disease. Comparative trials in this setting between zoledronic acid and denosumab have shown superior (in breast and in prostate cancer) or noninferior (in other solid tumors) skeletal-related event-prevention activity for denosumab. Osteonecrosis of the jaw is the most important side-effect of both compounds. Recent data also indicate the potential of zoledronic acid to reduce the recurrence rate in breast cancer. SUMMARY: Much progress has been accomplished for the treatment of tumor bone disease with bone resorption inhibitory drugs. Advances are now awaited in the setting of prevention of bone metastases.

Key concepts: Denosumab, Zoledronic acid, Medicine, Bisphosphonate, Osteonecrosis of the jaw, Bone resorption, Breast cancer, Bone Density Conservation Agents

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
New developments for treatment and prevention of bone metastases — Research Paper | ScholarLens